The eyonis™ Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying

November 7, 2024

We invite you to join this KOL webinar featuring two globally recognized U.S. pulmonology experts to get their views on the data from REALITY and how eyonis™ LCS may impact lung cancer diagnostics and treatment practices in the real world. Panelists include Prof. Anil Vachani, from the Hospital of the University of Pennsylvania, and Prof. Javier Zulueta, from the Icahn School of Medicine at Mt Sinai. Fredrik Brag, CEO of Median Technologies, also will participate and summarize the final REALITY results, which are going to be submitted in H1 2025 to regulators for U.S. and EU marketing authorizations for eyonis™ LCS.

Insights

Insights

Median is a disrupter in the area of medical imaging analysis. Find out more about what we are doing and how our technology works.

Webinars

Closing the Gap: Strategies for Resolving Imaging Discrepancies in Oncology Drug Trials

Articles

[Podcast] – Shaping Results through Imaging: Addressing Variability in Oncology Trials

This is an excerpt from our podcast “Shaping Results through Imaging: Addressing Variability in Oncology Trials”. Listen to full version of the podcast here : Connor Anderson – Project Manager II, Median Technologies: Thank you for joining this podcast. We are going to start the interview by setting the stage. Can you describe the role imaging…

Brochures

Introducing Median Imaging Lab

Scientific publications

Double reading performance and the impact of adjudication on progression-free survival estimations: Findings from a lung clinical trial

The FDA recommends Blinded Independent Central Review (BICR) with double reads for imaging in clinical trials, but inter-reader variability raises concerns.

Case studies

Accelerating Site Startups Across the Globe for Oncology Clinical Trial Imaging

White papers

Understanding Novel Response Patterns of Immunotherapies

Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.